Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs ResMed Inc. — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $31.06, while ResMed Inc. trades at $203.15 (market cap $28.80B). The key difference: ResMed Inc. pays a 1.21% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| GSG | RMD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $293.73 |
52-Week Low | $22.06 | $182.82 |
Market Cap | — | $28.80B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.
The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
